(Total Views: 630)
Posted On: 08/05/2020 10:55:55 AM
Post# of 154186
“At this point it seems all the $0.30 investors want to do on this board is tell stories.”
I’m a .30 investor and share plenty of stories, but most of those stories involve your concerns: paid advertisements, pointless CCs and poorly written PRs. This has been an issue for years, not a recent phenomenon. NP is the CEO and has proven over and over that he does things his way and doesn’t take feedback from the team very well (two patient BTD application, promising a 50 patient interim look into the severe trial, etc.).
Luckily, the science behind leronlimab has so far overcome these issues (HIV and cancer results). Although it’s hard at times when NP overshadows good results with his promises and inaccurate timelines. The same goes for COVID. Until full data is available, we play the waiting game and the game of NP making public promises that he often doesn’t fulfill.
I’m a .30 investor and share plenty of stories, but most of those stories involve your concerns: paid advertisements, pointless CCs and poorly written PRs. This has been an issue for years, not a recent phenomenon. NP is the CEO and has proven over and over that he does things his way and doesn’t take feedback from the team very well (two patient BTD application, promising a 50 patient interim look into the severe trial, etc.).
Luckily, the science behind leronlimab has so far overcome these issues (HIV and cancer results). Although it’s hard at times when NP overshadows good results with his promises and inaccurate timelines. The same goes for COVID. Until full data is available, we play the waiting game and the game of NP making public promises that he often doesn’t fulfill.
(7)
(0)
